Drug intelligence / Profile preview

XV-207

Development stage: Preclinical
Lead developer: Exavir Therapeutics
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intramuscular, Subcutaneous

Overview

XV-207 is an ultra-long-acting prodrug of tenofovir, a nucleotide reverse transcriptase inhibitor (NRTI), developed by Exavir Therapeutics and licensed to ViiV Healthcare. It utilizes a proprietary prodrug nanomedicine technology designed to enable dosing as infrequently as once every six months for the treatment and prevention of HIV-1 infection. By extending the pharmacokinetic profile of tenofovir, XV-207 aims to address challenges related to treatment adherence in HIV therapy. The compound was part of a 2024 settlement and license agreement between Exavir and ViiV Healthcare, which granted ViiV exclusive rights to develop and commercialize Exavir's portfolio of ultra-long-acting HIV candidates.

Other names: tenofovir prodrug

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on XV-207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XV-207.

Explore the full profile